1. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study 
Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, J.R.S. Tambiah, J. Hood, M.C. Hochberg 
Osteoarthritis and Cartilage 
Volume 25, Issue 10, Pages (October 2017)
DOI: /j.joca
Copyright © 2017 The Author(s) Terms and Conditions

2. Fig. 1
Flowchart of SM04690 dose escalation. Cohort 1 subjects were randomized at a 16:4 ratio to receive a single IA injection with either 0.03 mg SM04690 or PBO. Recruitment for Cohort 2 (0.07 mg) and Cohort 3 (0.23 mg) began after Week 12 blinded data review by a SRC. C1/2/3, Cohort 1/2/3; EOS, end of study.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 The Author(s) Terms and Conditions

3. Fig. 2 Flow chart of patient disposition.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 The Author(s) Terms and Conditions

4. Fig. 3
Mean (A) and median (B) change from baseline in WOMAC Total over time for all cohorts.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 The Author(s) Terms and Conditions

5. Fig. 4 Percent of OMERACT-OARSI responders at Weeks 12 and 24.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2017 The Author(s) Terms and Conditions